TY - JOUR
T1 - Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
AU - KConFab investigators
AU - HEBON Investigators
AU - SWE-BRCA Investigators
AU - Muranen, Taru A.
AU - Khan, Sofia
AU - Fagerholm, Rainer
AU - Aittomäki, Kristiina
AU - Cunningham, Julie M.
AU - Dennis, Joe
AU - Leslie, Goska
AU - McGuffog, Lesley
AU - Parsons, Michael T.
AU - Simard, Jacques
AU - Slager, Susan
AU - Soucy, Penny
AU - Easton, Douglas F.
AU - Tischkowitz, Marc
AU - Spurdle, Amanda B.
AU - Schmutzler, Rita K.
AU - Wappenschmidt, Barbara
AU - Hahnen, Eric
AU - Hooning, Maartje J.
AU - Singer, Christian F.
AU - Wagner, Gabriel
AU - Thomassen, Mads
AU - Pedersen, Inge Sokilde
AU - Domchek, Susan M.
AU - Nathanson, Katherine L.
AU - Lazaro, Conxi
AU - Rossing, Caroline Maria
AU - Andrulis, Irene L.
AU - Teixeira, Manuel R.
AU - James, Paul
AU - Garber, Judy
AU - Weitzel, Jeffrey N.
AU - Jakubowska, Anna
AU - Yannoukakos, Drakoulis
AU - John, Esther M.
AU - Southey, Melissa C.
AU - Schmidt, Marjanka K.
AU - Antoniou, Antonis C.
AU - Chenevix-Trench, Georgia
AU - Blomqvist, Carl
AU - Nevanlinna, Heli
N1 - Funding Information:
We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. The CIMBA data management and data analysis were supported by Cancer Research—UK grants C12292/A20861 and C12292/A11174. Genotyping for the OncoArray was funded by the government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministère de l'Économie, de la Science et de l’Innovation du Québec through Génome Québec, the Quebec Breast Cancer Foundation for the PERSPECTIVE project, the US National Institutes of Health (NIH; 1 U19 CA 148065 for the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract HHSN268201200008I), Cancer Research UK (C1287/A16563), the Odense University Hospital Research Foundation (Denmark), the National R&D Program for Cancer Control–Ministry of Health and Welfare (Republic of Korea; 1420190), the Italian Association for Cancer Research (AIRC; IG16933), the Breast Cancer Research Foundation, the National Health and Medical Research Council (Australia) and German Cancer Aid (110837). Detailed acknowledgements appear in the Supplementary note.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03–6.30, P = 3.1 × 10−9). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.
AB - Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03–6.30, P = 3.1 × 10−9). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.
UR - http://www.scopus.com/inward/record.url?scp=85090501112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090501112&partnerID=8YFLogxK
U2 - 10.1038/s41523-020-00185-6
DO - 10.1038/s41523-020-00185-6
M3 - Article
AN - SCOPUS:85090501112
SN - 2374-4677
VL - 6
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 44
ER -